news
NICE joins international collaboratives to respond to COVID-19
NICE in the UK has announced it will partner with international collaborations to share its work on COVID-19 and develop guidelines for healthcare professionals.
List view / Grid view
UK National Institute for Health and Care Excellence (NICE)
Filter the results
news
NICE recommends Vitrakvi (larotrectinib) for use on Cancer Drugs Fund
Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.
news
Professor Gillian Leng appointed NICE Chief Executive
Professor Gillian Leng has been appointed as the new Chief Executive of NICE and will take over from Sir Andrew Dillon in early April.
news
NICE fails to recommend pembrolizumab in final draft guidance
The UK NICE has not found pembrolizumab cost-effective for use on the NHS, after a review of evidence collected while the drug was available via the Cancer Drugs Fund.
news
Lenalidomide recommended for use with rituximab by NICE
NICE has given its positive opinion to lenalidomide in combination with rituximab as a 'chemotherapy-free' treatment for lymphoma.
news
NICE does not recommend polatuzumab vedotin to treat lymphoma
NICE has formed a negative opinion for Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine to treat diffuse large B-cell lymphoma.
news
NICE does not recommend esketamine for treatment-resistant depression
Esketamine nasal spray did not receive a positive opinion from NICE due to inadequate comparisons to other therapies and concerns over its cost effectiveness.
news
NICE argue for more histology-independent cancer drug evidence
Staff at NICE have co-authored a paper which suggests that new, histology-independent cancer treatments require more clinical evidence before approval recommendation by the institution.
news
NICE issues draft guidance, finding negative opinion for volanesorsen
Waylivra (volanesorsen) has not been recommended for treatment of familial chylomicronaemia syndrome, according to draft guidance from NICE.
news
NICE approves new tablet formulation for olaparib drug
The UK NICE has extended its approval for olaparib, updating its formulation from eight capsules twice a day to two tablets twice daily.